261 related articles for article (PubMed ID: 17934858)
1. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy.
Weinstock LB; Fern SE; Duntley SP
Dig Dis Sci; 2008 May; 53(5):1252-6. PubMed ID: 17934858
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms.
Weinstock LB; Klutke CG; Lin HC
Dig Dis Sci; 2008 May; 53(5):1246-51. PubMed ID: 17932763
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
4. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
[TBL] [Abstract][Full Text] [Related]
5. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
[TBL] [Abstract][Full Text] [Related]
6. Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth.
Weinstock LB; Walters AS
Sleep Med; 2011 Jun; 12(6):610-3. PubMed ID: 21570907
[TBL] [Abstract][Full Text] [Related]
7. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
8. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
[TBL] [Abstract][Full Text] [Related]
9. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
Weinstock LB; Geng B; Brandes SB
Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of restless legs syndrome in patients with irritable bowel syndrome.
Basu PP; Shah NJ; Krishnaswamy N; Pacana T
World J Gastroenterol; 2011 Oct; 17(39):4404-7. PubMed ID: 22110266
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
[TBL] [Abstract][Full Text] [Related]
12. Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?
Stoicescu A; Andrei M; Becheanu G; Stoicescu M; Nicolaie T; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):766-72. PubMed ID: 23272525
[TBL] [Abstract][Full Text] [Related]
13. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
[TBL] [Abstract][Full Text] [Related]
14. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.
Boltin D; Perets TT; Shporn E; Aizic S; Levy S; Niv Y; Dickman R
Ann Clin Microbiol Antimicrob; 2014 Oct; 13():49. PubMed ID: 25319626
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.
Triantafyllou K; Sioulas AD; Giamarellos-Bourboulis EJ
Mini Rev Med Chem; 2015; 16(3):186-92. PubMed ID: 26202193
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
Collins BS; Lin HC
J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
[TBL] [Abstract][Full Text] [Related]
18. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
Bae S; Lee KJ; Kim YS; Kim KN
J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
[TBL] [Abstract][Full Text] [Related]
19. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
Aziz I; Törnblom H; Simrén M
Curr Opin Gastroenterol; 2017 May; 33(3):196-202. PubMed ID: 28257307
[TBL] [Abstract][Full Text] [Related]
20. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
